Cargando…

Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case–control trials

The extracellular matrix is important for tumor invasion and metastasis. Normal function of the extracellular matrix depends on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). The objective of this meta-analysis was to assess the relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hong-Yan, Gu, Wei-Jun, Wang, Cheng-Zhi, Ji, Xiao-Jian, Mu, Yi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998479/
https://www.ncbi.nlm.nih.gov/pubmed/27310993
http://dx.doi.org/10.1097/MD.0000000000003904
_version_ 1782449952052477952
author Liu, Hong-Yan
Gu, Wei-Jun
Wang, Cheng-Zhi
Ji, Xiao-Jian
Mu, Yi-Ming
author_facet Liu, Hong-Yan
Gu, Wei-Jun
Wang, Cheng-Zhi
Ji, Xiao-Jian
Mu, Yi-Ming
author_sort Liu, Hong-Yan
collection PubMed
description The extracellular matrix is important for tumor invasion and metastasis. Normal function of the extracellular matrix depends on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). The objective of this meta-analysis was to assess the relationship between expression of MMP-9, MMP-2, and TIMP-2 and invasion of pituitary adenomas. We searched Pubmed, Embase, and the Chinese Biomedical Database up to October 2015. RevMan 5.1 software (Cochrane Collaboration, Copenhagen, Denmark) was used for statistical analysis. We calculated the standardized mean difference (SMD) for data expressed as mean ± standard deviation because of the difference in the detection method. Twenty-four studies (1320 patients) were included. MMP-9 expression was higher in the patients with invasive pituitary adenomas (IPAs) than patients with noninvasive pituitary adenomas (NIPAs) with detection methods of IHC [odds ratio (OR) = 5.48, 95% confidence interval (CI) = 2.61–11.50, P < 0.00001), and reverse transcriptase-polymerase chain reaction (SMD = 2.28, 95% CI = 0.91–3.64, P = 0.001). MMP-2 expression was also increased in patients with IPAs at the protein level (OR = 3.58, 95% CI = 1.63–7.87, P = 0.001), and RNA level (SMD = 3.91, 95% CI = 1.52–6.29, P = 0.001). Meta-analysis showed that there was no difference in TIMP-2 expression between invasive and NIPAs at the protein level (OR = 0.38, 95% CI = 0.06–2.26, P = 0.29). MMP-9 expression in prolactinomas and nonfunctioning pituitary adenomas was also no difference (OR = 1.03, 95% CI = 0.48–2.20, P = 0.95). The results indicated that MMP-9 and -2 may be correlated with invasiveness of pituitary adenomas, although their relationship with functional status of pituitary adenomas is still not clear. TIMP-2 expression in IPAs needs to be investigated further.
format Online
Article
Text
id pubmed-4998479
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-49984792016-09-02 Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case–control trials Liu, Hong-Yan Gu, Wei-Jun Wang, Cheng-Zhi Ji, Xiao-Jian Mu, Yi-Ming Medicine (Baltimore) 4300 The extracellular matrix is important for tumor invasion and metastasis. Normal function of the extracellular matrix depends on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). The objective of this meta-analysis was to assess the relationship between expression of MMP-9, MMP-2, and TIMP-2 and invasion of pituitary adenomas. We searched Pubmed, Embase, and the Chinese Biomedical Database up to October 2015. RevMan 5.1 software (Cochrane Collaboration, Copenhagen, Denmark) was used for statistical analysis. We calculated the standardized mean difference (SMD) for data expressed as mean ± standard deviation because of the difference in the detection method. Twenty-four studies (1320 patients) were included. MMP-9 expression was higher in the patients with invasive pituitary adenomas (IPAs) than patients with noninvasive pituitary adenomas (NIPAs) with detection methods of IHC [odds ratio (OR) = 5.48, 95% confidence interval (CI) = 2.61–11.50, P < 0.00001), and reverse transcriptase-polymerase chain reaction (SMD = 2.28, 95% CI = 0.91–3.64, P = 0.001). MMP-2 expression was also increased in patients with IPAs at the protein level (OR = 3.58, 95% CI = 1.63–7.87, P = 0.001), and RNA level (SMD = 3.91, 95% CI = 1.52–6.29, P = 0.001). Meta-analysis showed that there was no difference in TIMP-2 expression between invasive and NIPAs at the protein level (OR = 0.38, 95% CI = 0.06–2.26, P = 0.29). MMP-9 expression in prolactinomas and nonfunctioning pituitary adenomas was also no difference (OR = 1.03, 95% CI = 0.48–2.20, P = 0.95). The results indicated that MMP-9 and -2 may be correlated with invasiveness of pituitary adenomas, although their relationship with functional status of pituitary adenomas is still not clear. TIMP-2 expression in IPAs needs to be investigated further. Wolters Kluwer Health 2016-06-17 /pmc/articles/PMC4998479/ /pubmed/27310993 http://dx.doi.org/10.1097/MD.0000000000003904 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4300
Liu, Hong-Yan
Gu, Wei-Jun
Wang, Cheng-Zhi
Ji, Xiao-Jian
Mu, Yi-Ming
Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case–control trials
title Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case–control trials
title_full Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case–control trials
title_fullStr Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case–control trials
title_full_unstemmed Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case–control trials
title_short Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case–control trials
title_sort matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: a systematic review and meta-analysis of case–control trials
topic 4300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998479/
https://www.ncbi.nlm.nih.gov/pubmed/27310993
http://dx.doi.org/10.1097/MD.0000000000003904
work_keys_str_mv AT liuhongyan matrixmetalloproteinase9and2andtissueinhibitorofmatrixmetalloproteinase2ininvasivepituitaryadenomasasystematicreviewandmetaanalysisofcasecontroltrials
AT guweijun matrixmetalloproteinase9and2andtissueinhibitorofmatrixmetalloproteinase2ininvasivepituitaryadenomasasystematicreviewandmetaanalysisofcasecontroltrials
AT wangchengzhi matrixmetalloproteinase9and2andtissueinhibitorofmatrixmetalloproteinase2ininvasivepituitaryadenomasasystematicreviewandmetaanalysisofcasecontroltrials
AT jixiaojian matrixmetalloproteinase9and2andtissueinhibitorofmatrixmetalloproteinase2ininvasivepituitaryadenomasasystematicreviewandmetaanalysisofcasecontroltrials
AT muyiming matrixmetalloproteinase9and2andtissueinhibitorofmatrixmetalloproteinase2ininvasivepituitaryadenomasasystematicreviewandmetaanalysisofcasecontroltrials